Další formáty:
BibTeX
LaTeX
RIS
@article{1362715,
author = {Kiss, Igor and Mlčochová, Jitka and Bortlíček, Zbyněk and Poprach, Alexandr and Drábek, Jiří and Vychytilová, Petra and Svoboda, Marek and Büchler, Tomáš and Batko, Stanislav and Ryška, Aleš and Hajdúch, Marian and Slabý, Ondřej},
article_location = {Athens},
article_number = {9},
doi = {http://dx.doi.org/10.21873/anticanres.11063},
keywords = {KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients},
url = {http://ar.iiarjournals.org/content/36/9/4955.abstract},
volume = {36},
year = {2016}
}
TY - JOUR
ID - 1362715
AU - Kiss, Igor - Mlčochová, Jitka - Bortlíček, Zbyněk - Poprach, Alexandr - Drábek, Jiří - Vychytilová, Petra - Svoboda, Marek - Büchler, Tomáš - Batko, Stanislav - Ryška, Aleš - Hajdúch, Marian - Slabý, Ondřej
PY - 2016
TI - Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
JF - Anticancer Research
VL - 36
IS - 9
SP - 4955-4959
EP - 4955-4959
PB - INT INST ANTICANCER RESEARCH
SN - 02507005
KW - KRAS
KW - Metastatic colorectal cancer
KW - cetuximab
KW - miR-31-5p
KW - microRNA
KW - panitumumab
UR - http://ar.iiarjournals.org/content/36/9/4955.abstract
L2 - http://ar.iiarjournals.org/content/36/9/4955.abstract
N2 - Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.
ER -
KISS, Igor, Jitka MLČOCHOVÁ, Zbyněk BORTLÍČEK, Alexandr POPRACH, Jiří DRÁBEK, Petra VYCHYTILOVÁ, Marek SVOBODA, Tomáš BÜCHLER, Stanislav BATKO, Aleš RYŠKA, Marian HAJDÚCH a Ondřej SLABÝ. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. \textit{Anticancer Research}. Athens: INT INST ANTICANCER RESEARCH, 2016, roč.~36, č.~9, s.~4955-4959. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.11063.
|
